Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip
Methodology & AI Transparency ⓘ
Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip—coded clinically as M16.30 across Arthritis & Joints guidelines—combines urate-lowering titration [Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip M16.30] with structured follow-up of Serum Uric Acid in Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip (M16.30: (Gout Target)) (< 6.0 mg/dL (< 5.0 mg/dL with tophi) (M16.30)).
- 2 Real-world patient consensus: Clinical coding for Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip uses ICD-10 M16.30 across Arthritis & Joints specialty care.
- 3 Typical cash cost range: Workup highlights for Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip (M16.30): urate-lowering titration [Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip M16.30].
- 4 Top reported side effects / signs: Longitudinal Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip monitoring tracks Weight-Bearing Joint Radiograph [Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip M16.30] toward Preserved joint-space width (M16.30).
Ask our AI Specialists anything about Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip
What Is Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip?
Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip—coded clinically as M16.30 across Arthritis & Joints guidelines—combines urate-lowering titration [Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip M16.30] with structured follow-up of Serum Uric Acid in Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip (M16.30: (Gout Target)) (< 6.0 mg/dL (< 5.0 mg/dL with tophi) (M16.30)).
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip (M16.30) center on monosodium urate or in Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip (M16.30: calcium pyrophosphate crystal). targeted arthritis & joints interventions aim to normalize Weight-Bearing Joint Radiograph [Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip M16.30].
Common Symptoms & Clinical Signs
- • Presentation of Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip (M16.30): localized tendon or in Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip (M16.30: bursa tenderness limiting)
- • Secondary Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip clinical sign: activity-related deep aching in Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip (M16.30: joint pain in)
- • Symptom flares in Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip correlating with Weight-Bearing Joint Radiograph [Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip M16.30] deviation outside Preserved joint-space width (M16.30)
- • Functional arthritis & joints impact requiring urate-lowering titration [Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip M16.30] evaluation (M16.30)
Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M16.30 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NLM Clinical Tables |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip M16.30] | Preserved joint-space width (M16.30) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Uric Acid in Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip (M16.30: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M16.30) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip (M16.30: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M16.30) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Dantrolene Sodium Revonto, Dantrium • RxCUI 856656 | Skeletal Muscle Relaxant | 87% | $0.4048 | $ 11.73 /mo |
| Lyvispah (Baclofen) Lyvispah • RxCUI 2586589 | gamma-Aminobutyric Acid-ergic Agonist | 86% | $0.0361 | $ 11.10 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Laboratory markers predicting tofacitinib efficacy in Japanese patients with: What a 467-Participant Study Found Changes in laboratory parameters at M1 could potentially be used to assess whether tofacitinib therapy will be effective at M3; however, further investigation is needed. Modern rheumatology • 2025-04-08 • Phase III Randomized Trial | N = 467 | 93/100 | PMID 39657989 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Bimekizumab treatment resulted in sustained improvements in patient-reported symptoms, HRQOL, and work productivity up to 1 year in bDMARD-naïve and TNFi-IR patients with active PsA. The Journal of rheumatology • 2025-05-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39892885 ↗ |
| Can This Approach Help? Inside the Latest Research on Laryngeal Reinnervation vs Type I Thyroplasty in Unilateral Vocal Fold Paralysis The results from this study have provided us with the assurance that conducting an adequately powered randomized controlled clinical trial of laryngeal reinnervation versus type I thyroplasty for adults with UVFP in the UK is... The Laryngoscope • 2025-09-15 • Phase III Randomized Trial | N = 12 | 82/100 | PMID 40323143 ↗ |
| Can This Approach Help? Inside the Latest Research on VoiceS: voice quality after transoral CO 2 laser surgery versus single vocal cord Registered on 15 August 2019. Trials • 2022-10-27 • Phase III Randomized Trial | N = 34 | 82/100 | PMID 36303192 ↗ |
| Can This Approach Help? Inside the Latest Research on Long-Term Follow-Up After Unilateral Intravitreal Gene Therapy for Leber The treatment effect of lenadogene nolparvovec on BCVA and vision-related quality of life observed 96 weeks (2 years) after treatment in RESCUE and REVERSE was sustained at 3 years in RESTORE, with a maximum follow-up of 52. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society • 2021-09-01 • Phase III Randomized Trial | N = 76 | 82/100 | PMID 34415265 ↗ |
Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip Patient Community & “People Like Me” Threads
Filter Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip community threads and patient logs by age, biological sex, dosage, and treatment duration.